文献速递免疫规划卫生政策与健康促进

验证新提出的布莱顿协作组织疫苗诱导免疫性血小板减少症和血栓形成病例定义

Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis.
PubMed 文献 · Vaccine · 2024-07-12

本研究验证了布莱顿协作组织提出的疫苗诱导免疫性血小板减少症和血栓形成(VITT)病例定义,利用德国(n=71)、英国(n=220)、澳大利亚(n=203)和中国台湾(n=56)的裁定阳性VITT病例数据表,发现该定义各组分的阳性率较高(84%-100%),但在台湾病例中血栓或血栓栓塞标准仅占34%;该定义的灵敏度在德国和英国为100%,澳大利亚为92%,台湾为89%;这些发现支持该病例定义用于VITT的效力。

要点

  • 在德国、英国、澳大利亚和中国台湾的阳性VITT病例中,所提出定义各组分的阳性率普遍较高(84%-100%)。
  • 仅中国台湾VITT病例中血栓或血栓栓塞标准的出现率为34%。
  • 该病例定义的灵敏度在德国和英国为100%,澳大利亚为92%,中国台湾为89%。

核心结论

  • 这些发现支持该病例定义用于VITT的效力。

研究设计与样本

  • 本研究利用德国(n=71)、英国(n=220)、澳大利亚(n=203)和中国台湾(n=56)的裁定阳性VITT病例数据表,开发数据收集表以捕获VITT标准的变化并评估其诊断确定性水平。

主要发现

  • 在阳性病例中,所提出VITT定义各组分的阳性率较高(84%-100%),但中国台湾VITT病例中血栓或血栓栓塞标准的出现率仅为34%。
  • 该提出定义的灵敏度在德国和英国为100%,澳大利亚为92%,中国台湾为89%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a newly recognized syndrome mediated by anti-platelet factor 4 antibodies induced by Covid-19 adenovirus-vectored vaccines including ChAdOx1 nCoV-19 and Ad26.COV2.S. This study validated a proposed Brighton Collaboration case definition for VITT. A data collection form was developed and used to capture the variations in VITT criteria and assess their level of diagnostic certainty from adjudicated positive VITT case datasheets in Germany (n = 71), UK (n = 220), Australia (n = 203), and Taiwan (n = 56). We observed high prevalence of each component of the proposed VITT definition in positive cases (84%-100%), except for the occurrence of thrombosis or thromboembolism criterion in only 34% of VITT cases in Taiwan. The sensitivity of this proposed definition was 100% for Germany and UK, 92% for Australia, and 89% for Taiwan cases. These findings support the validity of this case definition for VITT.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Huang WT, Law B, Tran H, et al. Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis. Vaccine. 2024. PMID: 39003103. doi:10.1016/j.vaccine.2024.07.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。